Welcome to our dedicated page for Aspire Biopharma Holdings SEC filings (Ticker: ASBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspire Biopharma Holdings, Inc. (ASBP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑assisted context to help interpret complex documents. Aspire Biopharma is a Delaware‑incorporated biotechnology and biopharmaceutical company focused on a patent‑pending sublingual delivery platform for drugs and supplements, and its filings reflect both scientific ambitions and capital markets activity.
Through its registration statements on Form S‑1 and related amendments, Aspire details the structure of its convertible promissory notes, share registration for resale, and its status as a smaller reporting company and emerging growth company. Current reports on Form 8‑K describe material events such as the establishment and termination of an equity line of credit, recent sales of unregistered securities, changes in independent registered public accounting firms, and notices from Nasdaq regarding bid price and market value listing requirements.
Other filings, including the definitive proxy statement on Schedule 14A, outline shareholder proposals related to a reverse stock split, approval of share issuances under Nasdaq rules for the convertible notes, and potential adjournments to secure sufficient votes. These documents provide insight into how Aspire Biopharma manages its capital structure, maintains exchange listing compliance and seeks shareholder authorization for key corporate actions.
On this page, users can review ASBP’s 10‑K and 10‑Q reports when available for a fuller view of financial condition, risk factors and operational progress around its sublingual aspirin program, BUZZ BOMB™ supplement activities and broader pipeline. AI‑powered summaries highlight important terms in lengthy filings, explain the practical implications of financing arrangements, and surface notable items in Forms 3, 4 and 5 related to insider ownership and trading. Real‑time updates from EDGAR ensure that new Aspire Biopharma filings, amendments and exhibits are added as they are released, helping investors and researchers follow the company’s regulatory history efficiently.
Aspire Biopharma Holdings, Inc. (ASBPW) S-1 describes the company’s IPO-related capital structure, Trust Account holdings, related-party financing and post-transaction balances following its business combination activity. The company completed a Unit offering that funded a Trust Account (approximately $294.7 million initially) and recorded redemptions that reduced Trust Account balances to $6.67 million at December 31, 2024 and thereafter to amounts described as held for a Business Combination. The filing discloses substantial subscription agreement loans, working capital loans, multiple original-issue-discount (OID) notes to related parties, and convertible/debt instruments with debt discounts and fair-value adjustments recorded as large non-cash charges. Management reports a working capital deficit and notes substantial doubt about the company’s ability to continue as a going concern without additional financing. The record shows issuance and conversion of multiple share classes, sponsor/affiliate commitments, warrant pools outstanding, and material related-party transactions and contingent fees tied to the Business Combination.